

Roberta Mortarini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1308187/publications.pdf>

Version: 2024-02-01

63
papers

4,518
citations

117625

34
h-index

133252

59
g-index

65
all docs

65
docs citations

65
times ranked

7146
citing authors

#	ARTICLE	IF	CITATIONS
1	Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.		4
2	Immune Escape Mechanisms in Non Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3605.	3.7	92
3	An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells. <i>Oncogene</i> , 2019, 38, 4384-4396.	5.9	36
4	The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1011-1022.	4.2	36
5	Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Nonâ€“Small Cell Lung Cancer. <i>Cancer Research</i> , 2017, 77, 851-861.	0.9	49
6	Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 261-264.e4.	1.9	22
7	NFATc2 is an intrinsic regulator of melanoma dedifferentiation. <i>Oncogene</i> , 2016, 35, 2862-2872.	5.9	43
8	Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. <i>Oncotarget</i> , 2016, 7, 3947-3965.	1.8	45
9	Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells. <i>Oncotarget</i> , 2015, 6, 2779-2793.	1.8	56
10	Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. <i>Cell Death and Disease</i> , 2014, 5, e1434-e1434.	6.3	20
11	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. <i>Clinical Cancer Research</i> , 2014, 20, 5641-5651.	7.0	31
12	Enrichment of CD56dimKIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. <i>Nature Communications</i> , 2014, 5, 5639.	12.8	109
13	Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 2479-2485.	1.6	103
14	Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. <i>BMC Cancer</i> , 2014, 14, 560.	2.6	30
15	Role of Macrophage Targeting in the Antitumor Activity of Trabectedin. <i>Cancer Cell</i> , 2013, 23, 249-262.	16.8	721
16	Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. <i>Leukemia</i> , 2013, 27, 1677-1687.	7.2	26
17	IGKV3 Proteins as Candidate â€œOff-the-Shelfâ€•Vaccines for Kappa-Light Chainâ€“Restricted B-Cell Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 4080-4091.	7.0	14
18	Role of Apollon in Human Melanoma Resistance to Antitumor Agents That Activate the Intrinsic or the Extrinsic Apoptosis Pathways. <i>Clinical Cancer Research</i> , 2012, 18, 3316-3327.	7.0	27

#	ARTICLE	IF	CITATIONS
19	NFATc2 Is a Potential Therapeutic Target in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2652-2660.	0.7	41
20	Phase II study of sorafenib in patients with relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 108-119.	2.5	36
21	T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e783-e788.	1.6	8
22	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. <i>Clinical Cancer Research</i> , 2010, 16, 5862-5872.	7.0	56
23	Tumor-Reactive CD8+ Early Effector T Cells Identified at Tumor Site in Primary and Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 8378-8387.	0.9	52
24	Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage. <i>Clinical Cancer Research</i> , 2009, 15, 4085-4094.	7.0	29
25	Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.	1.4	99
26	The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. <i>Haematologica</i> , 2008, 93, 1523-1534.	3.5	63
27	Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1. <i>Cancer Research</i> , 2007, 67, 4271-4277.	0.9	59
28	Artificial Antigen Presenting Cells With Preclustered anti-CD28/-CD3/-LFA-1 Monoclonal Antibodies Are Highly Effective To Induce The Ex-Vivo Expansion Of Functional Human Antitumor T Cells. <i>Nature Precedings</i> , 2007, , .	0.1	0
29	Targeting Heat Shock Proteins on Cancer Cells: Selection, Characterization, and Cell-Penetrating Properties of a Peptidic GRP78 Ligand. <i>Biochemistry</i> , 2006, 45, 9434-9444.	2.5	172
30	APAF-1 signaling in human melanoma. <i>Cancer Letters</i> , 2006, 238, 168-179.	7.2	37
31	Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with ^{13}C cytokines. <i>Blood</i> , 2006, 107, 602-609.	1.4	15
32	Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. <i>Oncogene</i> , 2006, 25, 3357-3364.	5.9	157
33	Association of Antigen-Processing Machinery and HLA Antigen Phenotype of Melanoma Cells with Survival in American Joint Committee on Cancer Stage III and IV Melanoma Patients. <i>Cancer Research</i> , 2006, 66, 6405-6411.	0.9	56
34	Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles. <i>Cancer Research</i> , 2005, 65, 3428-3436.	0.9	53
35	Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination. <i>Clinical Cancer Research</i> , 2004, 10, 5381-5390.	7.0	98
36	Immunological and pathobiological roles of fibulin-1 in breast cancer. <i>Oncogene</i> , 2004, 23, 2153-2160.	5.9	45

#	ARTICLE	IF	CITATIONS
37	The paradox of T cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 855-64.	4.2	63
38	Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells Transduced Ex Vivo with a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial. <i>Human Gene Therapy</i> , 2003, 14, 1347-1360.	2.7	22
39	Differentiation of CD8+ T Cells from Tumor-Invaded and Tumor-Free Lymph Nodes of Melanoma Patients: Role of Common γ -Chain Cytokines. <i>Journal of Immunology</i> , 2003, 171, 2134-2141.	0.8	44
40	Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. <i>Cancer Research</i> , 2003, 63, 2535-45.	0.9	142
41	Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. <i>Haematologica</i> , 2003, 88, 1396-404.	3.5	11
42	Cancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?. <i>Journal of the National Cancer Institute</i> , 2002, 94, 805-818.	6.3	381
43	Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. <i>Immunological Reviews</i> , 2002, 188, 97-113.	6.0	246
44	Melanoma: The Milan Melanoma Cell Lines. , 2002, , 283-292.		1
45	The $\alpha 3 \beta 1$ integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp-9) activity. <i>International Journal of Cancer</i> , 2000, 87, 336-342.	5.1	245
46	The $\alpha 3 \beta 1$ integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp-9) activity. <i>International Journal of Cancer</i> , 2000, 87, 336-342.	5.1	4
47	Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex. <i>British Journal of Haematology</i> , 2000, 111, 344-350.	2.5	18
48	An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (CtI)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific CtIs but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions. <i>Journal of Experimental Medicine</i> , 1999, 190, 651-668.	8.5	186
49	High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 39-46.	4.2	18
50	Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides. <i>Aids</i> , 1998, 12, 261-268.	2.2	48
51	Expansion of Immunostimulatory Dendritic Cells from Peripheral Blood of Patients with Cancer. <i>Oncologist</i> , 1997, 2, 65-69.	3.7	5
52	Interaction with fibronectin regulates cytokine gene expression in human melanoma cells. , 1996, 66, 110-116.		14
53	Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis. , 1996, 66, 692-697.		45
54	The $\alpha 3 \beta 1$ Integrin Is Involved in Melanoma Cell Migration and Invasion. <i>Experimental Cell Research</i> , 1995, 219, 233-242.	2.6	126

#	ARTICLE	IF	CITATIONS
55	Multiple sub-sets of Cd4+ and Cd8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. <i>International Journal of Cancer</i> , 1994, 57, 56-62.	5.1	24
56	Tâ€cellâ€receptor engagement and tumor ICAMâ€1 upâ€regulation are required to byâ€pass low susceptibility of melanoma cells to autologous CTLâ€mediated lysis. <i>International Journal of Cancer</i> , 1993, 53, 994-1001.	5.1	33
57	??1-Integrins on Melanoma Clones Regulate the Interaction with Autologous Cytolytic T-Cell Clones. <i>Journal of Immunotherapy</i> , 1992, 12, 183-186.	2.4	8
58	Expansion of Major Histocompatibility Complex-Restricted Antimelanoma Cytotoxic T-Cell Lymphocyte Clones with Identical T-Cell Receptor from Tumor-Infiltrating Lymphocytes. <i>Journal of Immunotherapy</i> , 1992, 12, 207-211.	2.4	5
59	Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins. <i>International Journal of Cancer</i> , 1991, 47, 551-559.	5.1	89
60	Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. comparison with anti-proliferative activity by RIL1-Î², RTNF-Î±, RIFN-Î³, RIL4 and their combinations. <i>International Journal of Cancer</i> , 1990, 45, 334-341.	5.1	81
61	Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of icam-1 phenotype, vla profile and invasive ability. <i>International Journal of Cancer</i> , 1990, 46, 508-515.	5.1	74
62	Multiple VLA antigens on a subset of melanoma clones. <i>Human Immunology</i> , 1990, 28, 119-122.	2.4	8
63	Phenotypic profile of clones from early cultures of human metastatic melanomas and its modulation by recombinant interferon Î³. <i>International Journal of Cancer</i> , 1986, 38, 505-511.	5.1	35